Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. Insights on current treatment practice attitudes toward recently introduced and upcoming agents

Meeting Moderator

Mark Pegram, MD

Director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center,          Palo Alto, CA, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following breast cancer therapies were obtained

  • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
  • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
  • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of metastatic breast cancer was held in February 2020, in San Diego, CA, USA
  • Disease state and data presentations were developed in conjunction with Mark Pegram, MD, a medical expert from Stanford Women’s Cancer Center
  • The group of advisors comprised 13 community oncologists from the Southwest USA
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Explore Available and Upcoming Insight Reports

View Reports